BACKGROUND AND PURPOSE: Rescue of F508del-cystic fibrosis (CF) transmembrane conductance regulator (CFTR), the most common CF mutation, requires small molecules that overcome protein processing, stability and channel gating defects. Here, we investigate F508del-CFTR rescue by CFFT-004, a small molecule designed to independently correct protein processing and channel gating defects. EXPERIMENTAL APPROACH: Using CFTR-expressing recombinant cells and CF patient-derived bronchial epithelial cells, we studied CFTR expression by Western blotting and channel gating and stability with the patch-clamp and Ussing chamber techniques. KEY RESULTS: Chronic treatment with CFFT-004 improved modestly F508del-CFTR processing, but not its plasma membrane stability. By contrast, CFFT-004 rescued F508del-CFTR channel gating better than C18, an analogue of the clinically used CFTR corrector lumacaftor. Subsequent acute addition of CFFT-004, but not C18, potentiated F508del-CFTR channel gating. However, CFFT-004 was without effect on A561E-CFTR, a CF mutation with a comparable mechanism of CFTR dysfunction as F508del-CFTR. To investigate the mechanism of action of CFFT-004, we used F508del-CFTR revertant mutations. Potentiation by CFFT-004 was unaffected by revertant mutations, but correction was abolished by the revertant mutation G550E. These data suggest that correction, but not potentiation, by CFFT-004 might involve nucleotide-binding domain 1 of CFTR. CONCLUSIONS AND IMPLICATIONS: CFFT-004 is a dual-acting small molecule with independent corrector and potentiator activities that partially rescues F508del-CFTR in recombinant cells and native airway epithelia. The limited efficacy and potency of CFFT-004 suggests that combinations of small molecules targeting different defects in F508del-CFTR might be a more effective therapeutic strategy than a single agent.
BACKGROUND AND PURPOSE: Rescue of F508del-cystic fibrosis (CF) transmembrane conductance regulator (CFTR), the most common CF mutation, requires small molecules that overcome protein processing, stability and channel gating defects. Here, we investigate F508del-CFTR rescue by CFFT-004, a small molecule designed to independently correct protein processing and channel gating defects. EXPERIMENTAL APPROACH: Using CFTR-expressing recombinant cells and CF patient-derived bronchial epithelial cells, we studied CFTR expression by Western blotting and channel gating and stability with the patch-clamp and Ussing chamber techniques. KEY RESULTS: Chronic treatment with CFFT-004 improved modestly F508del-CFTR processing, but not its plasma membrane stability. By contrast, CFFT-004 rescued F508del-CFTR channel gating better than C18, an analogue of the clinically used CFTR corrector lumacaftor. Subsequent acute addition of CFFT-004, but not C18, potentiated F508del-CFTR channel gating. However, CFFT-004 was without effect on A561E-CFTR, a CF mutation with a comparable mechanism of CFTR dysfunction as F508del-CFTR. To investigate the mechanism of action of CFFT-004, we used F508del-CFTR revertant mutations. Potentiation by CFFT-004 was unaffected by revertant mutations, but correction was abolished by the revertant mutation G550E. These data suggest that correction, but not potentiation, by CFFT-004 might involve nucleotide-binding domain 1 of CFTR. CONCLUSIONS AND IMPLICATIONS: CFFT-004 is a dual-acting small molecule with independent corrector and potentiator activities that partially rescues F508del-CFTR in recombinant cells and native airway epithelia. The limited efficacy and potency of CFFT-004 suggests that combinations of small molecules targeting different defects in F508del-CFTR might be a more effective therapeutic strategy than a single agent.
Authors: Liying Cui; Luba Aleksandrov; Xiu-Bao Chang; Yue-Xian Hou; Lihua He; Tamas Hegedus; Martina Gentzsch; Andrei Aleksandrov; William E Balch; John R Riordan Journal: J Mol Biol Date: 2006-11-10 Impact factor: 5.469
Authors: S H Cheng; R J Gregory; J Marshall; S Paul; D W Souza; G A White; C R O'Riordan; A E Smith Journal: Cell Date: 1990-11-16 Impact factor: 41.582
Authors: J P Clancy; Steven M Rowe; Frank J Accurso; Moira L Aitken; Raouf S Amin; Melissa A Ashlock; Manfred Ballmann; Michael P Boyle; Inez Bronsveld; Preston W Campbell; Kris De Boeck; Scott H Donaldson; Henry L Dorkin; Jordan M Dunitz; Peter R Durie; Manu Jain; Anissa Leonard; Karen S McCoy; Richard B Moss; Joseph M Pilewski; Daniel B Rosenbluth; Ronald C Rubenstein; Michael S Schechter; Martyn Botfield; Claudia L Ordoñez; George T Spencer-Green; Laurent Vernillet; Steve Wisseh; Karl Yen; Michael W Konstan Journal: Thorax Date: 2011-08-08 Impact factor: 9.139
Authors: Fredrick Van Goor; Sabine Hadida; Peter D J Grootenhuis; Bill Burton; Jeffrey H Stack; Kimberly S Straley; Caroline J Decker; Mark Miller; Jason McCartney; Eric R Olson; Jeffrey J Wine; Ray A Frizzell; Melissa Ashlock; Paul A Negulescu Journal: Proc Natl Acad Sci U S A Date: 2011-10-05 Impact factor: 11.205
Authors: Paul D W Eckford; Mohabir Ramjeesingh; Steven Molinski; Stan Pasyk; Johanna F Dekkers; Canhui Li; Saumel Ahmadi; Wan Ip; Timothy E Chung; Kai Du; Herman Yeger; Jeffrey Beekman; Tanja Gonska; Christine E Bear Journal: Chem Biol Date: 2014-04-10
Authors: Nikhil T Awatade; Inna Uliyakina; Carlos M Farinha; Luka A Clarke; Karina Mendes; Amparo Solé; Juan Pastor; Maria Margarida Ramos; Margarida D Amaral Journal: EBioMedicine Date: 2014-12-17 Impact factor: 8.143
Authors: Jia Liu; Hermann Bihler; Carlos M Farinha; Nikhil T Awatade; Ana M Romão; Dayna Mercadante; Yi Cheng; Isaac Musisi; Walailak Jantarajit; Yiting Wang; Zhiwei Cai; Margarida D Amaral; Martin Mense; David N Sheppard Journal: Br J Pharmacol Date: 2018-02-22 Impact factor: 8.739
Authors: Onofrio Laselva; Giovanni Marzaro; Christian Vaccarin; Ilaria Lampronti; Anna Tamanini; Giuseppe Lippi; Roberto Gambari; Giulio Cabrini; Christine E Bear; Adriana Chilin; Maria C Dechecchi Journal: Front Pharmacol Date: 2018-07-04 Impact factor: 5.810
Authors: Jyoti Sharma; Ming Du; Eric Wong; Venkateshwar Mutyam; Yao Li; Jianguo Chen; Jamie Wangen; Kari Thrasher; Lianwu Fu; Ning Peng; Liping Tang; Kaimao Liu; Bini Mathew; Robert J Bostwick; Corinne E Augelli-Szafran; Hermann Bihler; Feng Liang; Jerome Mahiou; Josef Saltz; Andras Rab; Jeong Hong; Eric J Sorscher; Eric M Mendenhall; Candice J Coppola; Kim M Keeling; Rachel Green; Martin Mense; Mark J Suto; Steven M Rowe; David M Bedwell Journal: Nat Commun Date: 2021-07-16 Impact factor: 14.919